Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting

Journal of Community and Supportive Oncology

Volumn 14, Issue 4, 2016, Pages 141-147

  Navari, Rudolph M ^a,b   Nagy, Cindy K ^a   Le Rademacher, Jennifer ^c   Loprinzi, Charles L ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FOSAPREPITANT; GLUCOSE; OLANZAPINE; PALONOSETRON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; ESOPHAGUS CANCER; FEMALE; GLUCOSE BLOOD LEVEL; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; RADIATION DOSE DISTRIBUTION; RADIOTHERAPY INDUCED NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 84973341510     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0245     Document Type: Article

References (29)

1. Bloechl-Daum B, Deuson RR, Panagiotis M, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-4478.
2. Navari RM. Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs. 2013;73:249-262.
3. Navari RM. Palonosetron for the treatment of chemotherapy- induced nausea and vomiting. Expert Opin Pharmacother. 2014;15:2599-2608.
4. Aapro M, Carides A, Rapoport B. Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. Oncologist. 2015;20:450-458.
5. Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Design, Development and Therapy. 2015;9:155-151.
6. Navari RM. Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Therapy. 2015;15:1127-1133.
7. Tan L, Liu J, Liu X, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:1-7.
8. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): a randomized phase III trial. J Supp Oncol. 2011;9:188-195.
9. Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180-186.
10. Navari RM. Treatment of chemotherapy induced nausea. Community Oncol. 2012;9:20-26.
11. Poon M, Dennis K, DeAngelis C, et al. A prospective study of gastrointestinal radiation therapy-induced nausea and vomiting. Support Care Cancer. 2014;22:1493-1507.
12. Vidall C, Fernandez-Ortega P, Cortinovis D, et al. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. Support Care Cancer. 2015;23:3297-3305.
13. Ruhlmann CH, Iversen TZ, Okera M, et al. Multinational study exploring patients' perceptions of side effects induced by chemoradiotherapy. Radiother Oncol. 2015;117:333-337.
14. Dennis K, Poon M, Chow E. Nausea and vomiting induced by gastrointestinal radiation therapy: current status and future directions. Curr Opin Support Palliat Care. 2015;9:182-188.
15. Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer. 2011;19:S5-S14.
16. Dennis K, DeAngelis C, Jon F. et al. Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study. Curr Oncol. 2014;21:760-767.
17. Yan M, Kumachev A, Siu LL, et al. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. Eur J Cancer. 2015;51:1570-1579.
18. Zhu L, Yuan L, Wang H, et al. A meta-analysis of concurrent chemoradiotherapy for advanced esophageal cancer. Plos One. 2015. doi: 10.137/journal.pone.0128616 June 5.
19. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: The MD Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
20. Mizukami N, Yamanchi M, Koike K, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014;47:542-550.
21. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance: A221301, a randomized, double-blind, placebo-controlled trial. ASCO Palliative Care Symposium, abstract 176, Boston, October, 2015.
22. Hesketh PJ, Grunberg SM, Gralla RJ. et al. Te oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study group. J Clin Oncol. 2003;21:4112-4119.
23. Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK-1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy- induced nausea and vomiting: Efect of gender on treatment response. Support Care Cancer. 2006;14:354-360.
24. Warr DG, Hesketh PJ, Gralla, RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830.
25. Rappport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18:423-431.
26. Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: Time for more emphasis on nausea? Oncologist. 2015;20:576-583.
27. National Comprehensive Cancer Network. Antiemesis: clinical practice guidelines in oncology. www.nccn.org. 2015. Accessed October 21, 2015.
28. Goodrx website. www.goodrx.com Accessed October 21, 2015.
29. The Medical Letter. 2015;57:60.